CYRAMZA(TM) in combination with Paclitaxel significantly improves overall survival
Eli Lilly announced that results of the global Phase III trial of ramucirumab (CYRAMZA™) in combination with paclitaxel in patients with advanced gastric (stomach) cancer or gastroesophageal junction adenocarcinoma were published in the online version of The Lancet Oncology. September 18, 2014